Article
Source: Campus Sanofi

T1 Evidence in Children

Author : Sanofi

Editorial Team

Toujeo® Insulin Glargine 300U/ml is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. Discover the Toujeo^® Evidence in T1DM below and get access to patient supporting tools and materials for children with T1DM who have been prescribed Toujeo^®.

Randomised, Open Label Clinical Trial

Toujeo vs Insulin Glargine 100 U/mL

6 month, randomised, open label, double-arm, parallel group, non-inferiority study in 463 patients with T1DM.

Objective: To demonstrate non-inferiority of Toujeo^® vs insulin glargine 100 U/mL (a standard of care) in change of HbA1c from baseline to Week 26 in children/adolescents aged >6 years with T1DM.

Download clinical summary

Meta Analysis

Toujeo^® vs Insulin Glargine 100 U/mL

Post-hoc meta-analysis of three EDITION 6-month, Phase III, randomised clinical trials in a broad population including children aged 6+.

Post-hoc meta-analysis aim:Exploring the risk for severe hypoglycaemia with Toujeo^® vs insulin glargine 100 units/mL in the pool of studied patients with T1DM.

Edition 4 (549 adults), Edition Junior (463 children), Edition JP (245 adults).

Download clinical summary

See more from science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More about toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access patient materials